Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?

[1]  C. Paiva,et al.  LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer , 2016, World Journal of Urology.

[2]  H. Payne,et al.  The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK , 2016, World Journal of Urology.

[3]  K. Moretti,et al.  Men presenting with prostate‐specific antigen (PSA) values of over 100 ng/mL , 2016, BJU international.

[4]  E. Crawford,et al.  Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl , 2015, Expert opinion on drug metabolism & toxicology.

[5]  F. Saad,et al.  The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[6]  N. Corcoran,et al.  Adverse effects of androgen‐deprivation therapy in prostate cancer and their management , 2015, BJU international.

[7]  D. Dearnaley,et al.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Lowrance,et al.  Castration‐Resistant Prostate Cancer: AUA Guideline Amendment 2018 , 2015, The Journal of urology.

[9]  D. Perry-Keene.  Low testosterone in men , 2014 .

[10]  E. Crawford,et al.  Maximal testosterone suppression in prostate cancer--free vs total testosterone. , 2014, Urology.

[11]  B. Shayegan,et al.  Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[12]  A. Geldof,et al.  Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer , 2013, World Journal of Urology.

[13]  W. J. Morris,et al.  Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter? , 2012, BJU international.

[14]  L. Klotz,et al.  Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? , 2012, Current oncology.

[15]  L. Reis,et al.  Goserelin versus leuprolide in the chemical castration of patients with prostate cancer , 2012, International Urology and Nephrology.

[16]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[17]  V. Ficarra,et al.  Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients , 2009, Urologia Internationalis.

[18]  J. Morote,et al.  Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy , 2009, BJU international.

[19]  M. Miner,et al.  Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. , 2007, Cleveland Clinic journal of medicine.

[20]  M. Resnick,et al.  Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. , 2000, Urology.

[21]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[22]  W. Lowrance,et al.  Castration-resistant prostate cancer: AUA guideline amendment. , 2015, The Journal of urology.

[23]  Thomas Wiegel,et al.  Guidelines on Prostate Cancer , 2013 .

[24]  T. H. van der Kwast,et al.  [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.

[25]  L. Gomella.  Effective testosterone suppression for prostate cancer: is there a best castration therapy? , 2009, Reviews in urology.